Table 3.
Pathways significantly influenced by DAB (filtered at p<0.01). 111 and 4 pathways were up- or down-regulated in old rats (A), while 25 and 6 pathways were up- or down-regulated young rats (B)
| A | ||||
|---|---|---|---|---|
| Ingenuity canonical pathways | p-value | Ratio | Molecules | |
| Up | Dendritic cell maturation | 5.01E-21 | 1.73E-01 | PIK3R6, MYD88, HLA-DQA1, FCGR1A, PIK3R5, TLR9, FCER1G, CD40,TLR4, LOC100909593/RT1-DMa, IRF8, LOC100909630/RT1-DMb, STAT1, TYROBP, HLA-DRB5, TLR2, CD86, HLA-DOA, IL1B,HLA-DQB1, TNFRSF1B, COL1A2, B2M, HLA-DRA, FCGR2A, PIK3CG, HLA-A, FCGR2B, TLR3, IL1A, FCGR3A/FCGR3B |
| TREM1 signaling | 7.94E-18 | 2.67E-01 | TLR7, MYD88, IL1B, CASP1, TLR9, CD40, Naip1 (includes others), TLR4, LAT2, FCGR2B, TLR3, NLRP3, TYROBP, CCL2, Nlrp1a, TLR10, TLR2, CD86, NLRC4, CIITA | |
| Role of pattern recognition receptors in recognition of bacteria and viruses | 3.16E-15 | 1.73E-01 | PIK3R6, TLR7, C3, MYD88, IL1B, C1QB, OAS2, PIK3R5, CASP1, TLR9, C3AR1, C1QA, PIK3CG, TLR4, C1QC, SYK, TLR3, C5AR1, NLRP3, IL1A, TLR2, NLRC4 | |
| Complement system | 2.51E-12 | 3.24E-01 | ITGAM, C1QC, C4A/C4B, C2,C3, C5AR1, C1QB, ITGB2, SERPING1, CFH, C3AR1, C1QA | |
| NF-κB signaling | 8.70E-10 | 1.1E-01 | TNFSF13B, PIK3R6, TLR7, MYD88, IL1B, TNFRSF1B, PIK3R5, TLR9, FCER1G, CD40, PIK3CG, TLR4, CARD11, TLR3, MAP3K1, IL1A, TLR10, TLR2, CASP8 | |
| Toll-like receptor signaling | 1.35E-06 | 1.35E-01 | TLR4, TLR7, MYD88, IL1B, TLR3, MAP3K1, IL1A, TLR9, TLR10, TLR2 | |
| Granulocyte adhesion and diapedesis | 7.70E-06 | 7.91E-02 | IL1RL1, ITGAM, ITGAL, IL1B, CXCL10, TNFRSF1B, CSF3R,ITGB2, CXCL17, C5AR1, CXCL13, CCL2, IL1A, CXCL16, ADCY4, MYD88, ADCY7, MAP3K1, IL1A, GNA15 | |
| IL-1 signaling | 7.76E-03 | 6.59E-02 | ADCY4, MYD88, ADCY7, MAP3K1, IL1A, GNA15 | |
| iNOS signaling | 9.55E-03 | 9.09E-02 | TLR4, IRF1, MYD88, STAT1 | |
| etc. | ||||
| Down | IL-17 signaling | 2.14E-03 | 4.17E-02 | PTGS2, TIMP1, MUC5B |
| TGF-β signaling | 3.71E-03 | 3.45E-02 | INHBA, ACVR1C, PMEPA1 | |
| Anandamide degradation | 7.08E-03 | 5E-01 | FAAH | |
| Inhibition of matrix metalloproteases | 8.51E-03 | 5.13E-02 | MMP9, TIMP1 | |
| B | ||||
| Ingenuity canonical patdways | p-value | Ratio | Molecules | |
| Up | FXR/RXR activation | 1.32E-10 | 7.09E-02 | GC, APOB, APOA1, FETUB, SERPINA1, HPX, SULT2A1, AMBP, ALB |
| LXR/RXR activation | 2.63E-09 | 6.61E-02 | GC, APOB, APOA1, SERPINA1, HPX, AMBP, ECHS1, ALB | |
| Acute phase response signaling | 6.76E-07 | 4.14E-02 | FGB, APOA1, SERPINA1, HPX, AMBP, ALB, FGG | |
| Nicotine degradation III | 2.00E-05 | 7.41E-02 | UGT2B7, CYP3A5, CYP2C19, CYP1B1 | |
| Melatonin degradation I | 2.51E-05 | 7.02E-02 | UGT2B7, CYP3A5, CYP2C19, CYP1B1 | |
| Superpathway of melatonin degradation | 2.51E-05 | 6.45E-02 | UGT2B7, CYP3A5, CYP2C19, CYP1B1 | |
| Nicotine degradation II | 3.72E-05 | 6.35E-02 | UGT2B7, CYP3A5, CYP2C19, CYP1B1 | |
| Bupropion degradation | 5.50E-05 | 1.2E-01 | CYP3A5, CYP2C19, CYP1B1 | |
| Acetone degradation I (to methylglyoxal) | 6.92E-05 | 1.11E-01 | CYP3A5, CYP2C19, CYP1B1 | |
| etc. | ||||
| Down | Hepatic fibrosis/hepatic stellate cell activation | 8.13E-04 | 4.37E-02 | MYH3, COL8A2, FGF1, MMP2, COL28A1, TGFBR1, COL8A1, IGF2 |
| Leukocyte extravasation signaling | 5.50E-03 | 3.54E-02 | ARHGAP6, MMP2, CLDN3, ARHGAP8/PRR5-ARHGAP8, MAPK13, CLDN2, MMP14 | |
| G-protein coupled receptor signaling | 5.46E-03 | 3.12E-02 | DRD1, DRD2, CAMK2D, HTR2C, ADRA2A, GRM8, RGS4, NPR3 | |
| Inhibition of matrix metalloproteases | 8.32E-03 | 7.69E-02 | MMP2, THBS2, MMP14 | |
| cAMP-mediated signaling | 9.33E-03 | 3.2E-02 | DRD1, DRD2, CAMK2D, ADRA2A, GRM8, RGS4, NPR3 | |
| Gαi signaling | 9.33E-03 | 4.17E-02 | DRD2, ADRA2A, GRM8, RGS4, NPR3 | |
Enrichment ratio is calculated by the number of genes from the list that maps to the pathway divides to the total number of genes that map to the same pathway.